Gapping up
In reaction to earnings/guidance:
- MNDY +20.2%, STOK +8.9%, YOU +4.1%, TSEM +3.4%, ROIV +2.7%, TSN +1.8%, ERJ +1.2%
Other news:
- SI +17.1% (issues statement regarding its exposure to FTX)
- HCM +15.6% (Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China)
- PFSW +5.1% (updates the ex-dividend date for its previously announced special dividend of $4.50/share to December 16)
- KZR +5% (Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022)
- VRDN +4.8% (data from ongoing phase 1/2 trial evaluating vrdn-001 in patients with thyroid eye disease)
- BZUN +2.5% (reports total record high total order value for the 2022 11.11 Shopping Festival)
- CVAC +2.2% (presented preliminary data from Phase 1 study expansion of oncology candidate CV8102)
- MSGS +2.1% (aiming to introduce paid application)
- DSKE +2% (entered into an agreement with its founder, Mr. Don R. Daseke, and affiliates, to repurchase their total holdings (17,932,725 shares) at $6.00 per share)
- AZN +1.4% (reports Imfinzi plus chemotherapy recommended for approval in the EU by CHMP as first immunotherapy regimen for advanced biliary tract cancer)
- KALV +1.1% (presents patient-focused data at American College of Allergy, Asthma & Immunology 2022 Meeting)
- MSTR +1% (FTX bankruptcy spillover)
Analyst comments:
- OSH +2.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- BEEM +1.1% (upgraded to Buy from Neutral at H.C. Wainwright)